Cell Autonomous Complement Activation Drives Senescence in Human Podocytes (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #TH-PO0432; Pres time: Oct 22, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Methods Human immortalized podocytes were treated with Adriamycin (ADR) alone or in combination with Dapaglifozin (a SGLT2 inhibitor), Cp40 (a C3 convertase inhibitor), a C3a receptor antagonist (C3aRA), or Iptacopan (a Factor B inhibitor) for 24 hours...Notably, ADR treated podocytes exhibited cell intrinsic C3 cleavage and production of Bb fragment, both of which were diminished by Dapagliflozin or Cp40. Conclusion The rapid expansion of novel therapeutics, including complement targeting agents, is reshaping the treatment landscape for glomerular kidney diseases. Our findings show that podocyte intrinsic complement activation drives ADR induced senescence and injury, identifying this pathway as a promising therapeutic target in glomerular pathology."
Chronic Kidney Disease • Glomerulonephritis • Inflammation • Lupus Nephritis • Nephrology • Renal Disease • CASP3 • CDKN1A
|
|
Giuseppe Castellano; Min Li; Dario Margeri; Farzaneh Inanloo Nigi Jak; Margherita Di Naro; Caterina Lonati; Deborah Mattinzoli; Silvia Armelloni; Masami Ikehata; Carlo Alfieri; Francesca Zanoni; Manuel Alfredo Podestà; John Lambris; Matteo Stravalaci
|